Skip to content

Category: In the News

Pink Sheet — FDA Panel To Consider Strategies For Timely Completion Of Accelerated Approval Confirmatory Trials

A US Food and Drug Administration advisory committee review of two Acrotech Biopharma LLC accelerated approval drugs with long-overdue confirmatory trial requirements may provide the clearest insight yet into how the Oncology Center of Excellence interprets the “due diligence” requirement for such studies and how sponsors’ planning and implementation strategies may factor into this determination. The Oncologic…

Pink Sheet — Accelerated Approval: US FDA Writing Guidance On What ‘Ongoing’ Means For Confirmatory Trials

Oncology sponsors soon will better understand the meaning of “ongoing” in the context of a confirmatory trial and the potential barrier it presents to accelerated approval. OCE Director Richard Pazdur said 14 November that guidance on the meaning of “ongoing” is in development – and he also emphasized that without an ongoing confirmatory trial, an…

STAT — To get things done fast at FDA: ‘Don’t tell anybody,’ cancer chief says

The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives. Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many. To cut through that bureaucracy, Pazdur has…

Endpoints News — New NIH chief stresses focus on obesity, clinical trial challenges

The new leader of the NIH is worried about obesity. Monica Bertagnolli, who was confirmed as the new NIH director last week, said that during her first meeting with the NIH institute heads, she posed a question: “Is there anybody in this room who isn’t worried about obesity?” “The answer is really no,” she told the…

STAT — New NIH head says government has fallen behind pharma on clinical trials

The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure” that enrollment in government-funded clinical trials has lagged behind those funded by the pharmaceutical industry. “If you just look at the number of patients who go on government-funded trials, it’s been completely flat over the last decade,” she said at a meeting…

POLITICO — Report calls on FDA to lead task force on post-approval trials

The nonprofit Reagan-Udall Foundation that advises the FDA is recommending the agency lead an inter-agency and industry task force to streamline and strengthen post-approval studies of drugs and devices. For a variety of reasons, many post-approval studies are never completed or take years longer than expected and FDA Commissioner Robert Califf said Tuesday that data…

STAT — Senate confirms Monica Bertagnolli as NIH director

Longtime cancer doctor Monica Bertagnolli is finally heading to the National Institutes of Health director’s office after a nearly two-year effort to install a permanent leader atop the $48 billion science agency. The Senate voted 62-36 Tuesday to confirm her nomination, giving the White House clearance to officially name Bertagnolli the institute’s director, the second…

Bloomberg Law — Senate Confirms Biden’s Pick to Lead Medical Research Agency

Monica Bertagnolli will be the second woman to serve as a confirmed director of the National Institutes of Health, the nation’s premier federal medical research agency. Bertagnolli was confirmed to the post by a 62-36 vote Tuesday. She replaces Lawrence Tabak, who has been acting director for nearly two years. Bertagnolli’s appointment comes at a…

Business Wire — City of Hope Vice Physician-in-Chief Edward S. Kim, M.D., M.B.A, Recognized as a Top Diversity Leader in U.S. Healthcare

Kim is honored by Modern Healthcare magazine for lifelong advocacy for equity in cancer research and care LOS ANGELES–(BUSINESS WIRE)–City of Hope, one of the largest cancer research and treatment organizations in the United States, announced today that Vice Physician-in-Chief Edward S. Kim, M.D., M.B.A., has been named a 2023 Modern Healthcare Top Diversity Leader. The prestigious…

The Cancer Letter — High-risk investments by ARPA-H aim to catalyze a new era in cancer research

The recently announced ARPA-H Health Innovation Network would include hospitals, investors, and healthcare organizations—all entities that can contribute to developing and commercializing technologies that may improve patient outcomes. “Working with the federal government, loud and clear feedback from the community is very hard—it’s these very complex interactions with the government,” ARPA-H Director Renee Wegrzyn said…